6 Literaturverzeichnis

65
6 Literaturverzeichnis
1.
Abd El-Rehim DM, Pinder SE et al. Expression and co-expression of the members of the
epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer
91 (8): 1532-1542, 2004.
2.
Allred DC, Clark GM et al. Overexpression of HER-2/neu and its relationship with other
prognostic factors change during the progression of in situ to invasive breast cancer. Hum
Pathol 23 (9): 974-979, 1992.
3.
Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal
diversification through combinatorial ligand-receptor interactions. FEBS Lett 410 (1): 8386, 1997.
4.
Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman
cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (18 Suppl): 32S-40S,
2001.
5.
Bacus SS, Chin D et al. Type 1 receptor tyrosine kinases are differentially phosphorylated
in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol
148 (2): 549-558, 1996.
6.
Baselga J, Albanell J et al. Mechanism of action of trastuzumab and scientific update.
Semin Oncol 28 (5 Suppl 16): 4-11, 2001.
7.
Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer
therapy. Pharmacol Ther 64 (1): 127-154, 1994.
8.
Baselga J, Tripathy D et al. Phase II study of weekly intravenous recombinant humanized
anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic
breast cancer. J Clin Oncol 14 (3): 737-744, 1996.
9.
Battaglia F, Scambia G et al. Epidermal growth factor receptor in human breast cancer:
correlation with steroid hormone receptors and axillary lymph node involvement. Eur J
Cancer Clin Oncol 24 (11): 1685-1690, 1988.
10.
Bell R. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 63
Suppl 1: 39-46, 2002.
11.
Birner P, Oberhuber G et al. Evaluation of the United States Food and Drug
Administration-approved scoring and test system of HER-2 protein expression in breast
cancer. Clin Cancer Res 7 (6): 1669-1675, 2001.
12.
Busmanis I, Feleppa F et al. Analysis of cerbB2 expression using a panel of 6
commercially available antibodies. Pathology 26 (3): 261-267, 1994.
13.
Carlomagno C, Perrone F et al. c-erb B2 overexpression decreases the benefit of adjuvant
tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin
Oncol 14 (10): 2702-2708, 1996.
66
14.
Carter P, Presta L et al. Humanization of an anti-p185HER2 antibody for human cancer
therapy. Proc Natl Acad Sci U S A 89 (10): 4285-4289, 1992.
15.
Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast
cancer. Semin Oncol 15 (2 Suppl 1): 20-25, 1988.
16.
Clark GM, Sledge GW, Jr. et al. Survival from first recurrence: relative importance of
prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5 (1): 55-61, 1987.
17.
Clarke RB, Howell A et al. Dissociation between steroid receptor expression and cell
proliferation in the human breast. Cancer Res 57 (22): 4987-4991, 1997.
18. Clynes RA, Towers TL et al. Inhibitory Fc receptors modulate in vivo cytoxicity against
tumor targets. Nat Med 6 (4): 443-446, 2000.
19.
Cobleigh MA, Vogel CL et al. Multinational study of the efficacy and safety of humanized
anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic
breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol
17 (9): 2639-2648, 1999.
20.
Cohen S, Taylor JM. Epidermal growth factor: chemical and biological characterization.
Recent Prog Horm Res 30 (0): 533-550, 1974.
21.
Costa S, Stamm H et al. Predictive value of EGF receptor in breast cancer. Lancet 2
(8622): 1258, 1988.
22.
Cowley SM, Parker MG. A comparison of transcriptional activation by ER α and ER β. J
Steroid Biochem Mol Biol 69 (1-6): 165-175, 1999.
23.
Dabrosin C, Margetts PJ, Gauldie J. Estradiol increases extracellular levels of vascular
endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 107 (4): 535540, 2003.
24.
DAKO HercepTest: A Manual for Interpretation. DAKO: 2000.
25.
Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal
growth factor receptor in normal human tissues. Lab Invest 55 (5): 588-592, 1986.
26.
Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for
breast cancer. Endocr Relat Cancer 8 (3): 191-195, 2001.
27.
Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of
the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.
Oncogene 2 (3): 273-277, 1988.
28.
Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene
product directly mediate anti-tumor effects in vivo. Oncogene 2 (4): 387-394, 1988.
29.
Drebin JA, Link VC et al. Down-modulation of an oncogene protein product and reversion
of the transformed phenotype by monoclonal antibodies. Cell 41 (3): 697-706, 1985.
67
30.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an
overview of the randomised trials. Lancet 351 (9114): 1451-1467, 1998.
31.
Edgerton SM, Moore D et al. erbB-2 (HER-2) and breast cancer progression. Appl
Immunohistochem Mol Morphol 11 (3): 214-221, 2003.
32.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of
histological grade in breast cancer: experience from a large study with long-term followup. Histopathology 19 (5): 403-410, 1991.
33. Esteva FJ, Hortobagyi GN et al. Expression of erbB/HER receptors, heregulin and P38 in
primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7 (3):
171-177, 2001.
34.
Fendly BM, Winget M et al. Characterization of murine monoclonal antibodies reactive to
either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res
50 (5): 1550-1558, 1990.
35.
Ferlay J, Bray F et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence
worldwide. IARC Cancer Base No 5 IARC Press (Version 1.0): 2001.
36.
Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA
288 (3): 366-368, 2002.
37.
Foekens JA, Portengen H et al. Prognostic value of receptors for insulin-like growth factor
1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49 (24 Pt
1): 7002-7009, 1989.
38.
Fuchs IB, Loebbecke M et al. HER2 in brain metastases: issues of concordance, survival,
and treatment. J Clin Oncol 20 (19): 4130-4133, 2002.
39.
Fuchs IB, Siemer I et al. Epidermal growth factor receptor changes during breast cancer
metastasis. Anticancer Res 26 (6B): 4397-4401, 2006.
40.
Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland
Biol Neoplasia 6 (4): 407-417, 2001.
41.
Fuqua SA, Wiltschke C et al. A hypersensitive estrogen receptor-α mutation in
premalignant breast lesions. Cancer Res 60 (15): 4026-4029, 2000.
42.
Gancberg D, Di Leo A et al. Comparison of HER-2 status between primary breast cancer
and corresponding distant metastatic sites. Ann Oncol 13 (7): 1036-1043, 2002.
43. Gasparini G, Gullick WJ et al. c-erbB-3 and c-erbB-2 protein expression in node-negative
breast carcinoma – an immunocytochemical study. Eur J Cancer 30A (1): 16-22, 1994.
44. Gilbertson RJ, Perry RH et al. Prognostic significance of HER2 and HER4 coexpression in
childhood medulloblastoma. Cancer Res 57 (15): 3272-3280, 1997.
68
45.
Goldhirsch A, Glick JH et al. Meeting highlights: International Consensus Panel on the
Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant
Therapy of Primary Breast Cancer. J Clin Oncol 19 (18): 3817-3827, 2001.
46.
Goldstein NI, Prewett M et al. Biological efficacy of a chimeric antibody to the epidermal
growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (11): 13111318, 1995.
47. Graus-Porta D, Beerli RR et al. ErbB-2, the preferred heterodimerization partner of all
ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (7): 1647-1655, 1997.
48.
Grimaux M, Romain S et al. Prognostic value of epidermal growth factor receptor in nodepositive breast cancer. Breast Cancer Res Treat 14 (1): 77-90, 1989.
49.
Gullick WJ, Marsden JJ et al. Expression of epidermal growth factor receptors on human
cervical, ovarian, and vulval carcinomas. Cancer Res 46 (1): 285-292, 1986.
50. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and
receptors and their role in breast cancer. Breast Cancer Res Treat 52 (1-3): 43-53, 1998.
51.
Gustafsson JA. Estrogen receptor β – a new dimension in estrogen mechanism of action. J
Endocrinol 163 (3): 379-383, 1999.
52.
Gusterson B, Cowley G et al. Cellular localisation of human epidermal growth factor
receptor. Cell Biol Int Rep 8 (8): 649-658, 1984.
53.
Gusterson BA, Gelber RD et al. Prognostic importance of c-erbB-2 expression in breast
cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (7): 10491056, 1992.
54. Guy CT, Webster MA et al. Expression of the neu protooncogene in the mammary
epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89
(22): 10578-10582, 1992.
55.
Guy PM, Platko JV et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine
kinase activity. Proc Natl Acad Sci U S A 91 (17): 8132-8136, 1994.
56.
Hancock MC, Langton BC et al. A monoclonal antibody against the c-erbB-2 protein
enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and
ovarian tumor cell lines. Cancer Res 51 (17): 4575-4580, 1991.
57.
Harris LN, Liotcheva V et al. Comparison of methods of measuring HER-2 in metastatic
breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19 (6): 16981706, 2001.
58.
Harvey JM, Clark GM et al. Estrogen receptor status by immunohistochemistry is superior
to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast
cancer. J Clin Oncol 17 (5): 1474-1481, 1999.
59.
Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal
growth factor receptors. J Clin Invest 74 (2): 647-651, 1984.
69
60.
Heppner GH. Tumor cell societies. J Natl Cancer Inst 81 (9): 648-649, 1989.
61.
Hudelist G, Singer CF et al. Co-expression of ErbB-family members in human breast
cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast
Cancer Res Treat 80 (3): 353-361, 2003.
62.
Hudziak RM, Lewis GD et al. p185HER2 monoclonal antibody has antiproliferative effects
in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9
(3): 1165-1172, 1989.
63. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor
receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl
Acad Sci U S A 84 (20): 7159-7163, 1987.
64.
Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim
Biophys Acta 1198 (2-3): 165-184, 1994.
65. Iwao K, Miyoshi Y et al. Quantitative analysis of estrogen receptor-β mRNA and its
variants in human breast cancers. Int J Cancer 88 (5): 733-736, 2000.
66.
Izumi Y, Xu L et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature
416 (6878): 279-280, 2002.
67.
Jacobs TW, Gown AM et al. Specificity of HercepTest in determining HER-2/neu status of
breast cancers using the United States Food and Drug Administration-approved scoring
system. J Clin Oncol 17 (7): 1983-1987, 1999.
68.
Jacobs TW, Prioleau JE et al. Loss of tumor marker-immunostaining intensity on stored
paraffin slides of breast cancer. J Natl Cancer Inst 88 (15): 1054-1059, 1996.
69. John HA, Birnstiel ML, Jones KW. RNA-DNA hybrids at the cytological level. Nature 223
(206): 582-587, 1969.
70.
Kainulainen V, Sundvall M et al. A natural ErbB4 isoform that does not activate
phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol
Chem 275 (12): 8641-8649, 2000.
71.
Karayiannakis AJ, Bastounis EA et al. Immunohistochemical detection of oestrogen
receptors in ductal carcinoma in situ of the breast. Eur J Surg Oncol 22 (6): 578-582, 1996.
72.
Kato S, Masuhiro Y et al. Molecular mechanism of a cross-talk between oestrogen and
growth factor signalling pathways. Genes Cells 5 (8): 593-601, 2000.
73.
Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects.
Adv Cancer Res 55: 87-132, 1990.
74.
Kew TY, Bell JA et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 82
(6): 1163-1170, 2000.
75.
Khan SA, Rogers MA et al. Estrogen receptor expression in benign breast epithelium and
breast cancer risk. J Natl Cancer Inst 90 (1): 37-42, 1998.
70
76.
Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225).
Curr Opin Oncol 13 (6): 506-513, 2001.
77.
Klapper LN, Kirschbaum MH et al. Biochemical and clinical implications of the
ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79, 2000.
78.
Klijn JG, Berns PM et al. The clinical significance of epidermal growth factor receptor
(EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13 (1): 3-17,
1992.
79.
Knight WA, Livingston RB et al. Estrogen receptor as an independent prognostic factor for
early recurrence in breast cancer. Cancer Res 37 (12): 4669-4671, 1977.
80.
Knowlden JM, Gee JM et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine
responsive phenotype in clinical breast cancer. Oncogene 17 (15): 1949-1957, 1998.
81. Koenders PG, Beex LV et al. Steroid hormone receptor activity of primary human breast
cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res
Treat 18 (1): 27-32, 1991.
82. Konecny G, Pauletti G et al. Quantitative association between HER-2/neu and steroid
hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst
95 (2): 142-153, 2003.
83.
Kraus MH, Issing W et al. Isolation and characterization of ERBB3, a third member of the
ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of
human mammary tumors. Proc Natl Acad Sci U S A 86 (23): 9193-9197, 1989.
84.
Kurebayashi J, Okubo S et al. Inhibition of HER1 signaling pathway enhances antitumor
effect of endocrine therapy in breast cancer. Breast Cancer 11 (1): 38-41, 2004.
85. Kuukasjarvi T, Karhu R et al. Genetic heterogeneity and clonal evolution underlying
development of asynchronous metastasis in human breast cancer. Cancer Res 57 (8): 15971604, 1997.
86.
Kuukasjarvi T, Kononen J et al. Loss of estrogen receptor in recurrent breast cancer is
associated with poor response to endocrine therapy. J Clin Oncol 14 (9): 2584-2589, 1996.
87.
Lane HA, Beuvink I et al. ErbB2 potentiates breast tumor proliferation through modulation
of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth
dependency. Mol Cell Biol 20 (9): 3210-3223, 2000.
88.
Lane HA, Motoyama AB et al. Modulation of p27/Cdk2 complex formation through 4D5mediated inhibition of HER2 receptor signaling. Ann Oncol 12 Suppl 1: S21-S22, 2001.
89.
Lawson JS, Field AS et al. Low oestrogen receptor α expression in normal breast tissue
underlies low breast cancer incidence in Japan. Lancet 354 (9192): 1787-1788, 1999.
90. Leal CB, Schmitt FC et al. Ductal carcinoma in situ of the breast. Histologic categorization
and its relationship to ploidy and immunohistochemical expression of hormone receptors,
p53, and c-erbB-2 protein. Cancer 75 (8): 2123-2131, 1995.
71
91.
Lebeau A, Deimling D et al. Her-2/neu analysis in archival tissue samples of human breast
cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin
Oncol 19 (2): 354-363, 2001.
92.
Lemoine NR, Barnes DM et al. Expression of the ERBB3 gene product in breast cancer. Br
J Cancer 66 (6): 1116-1121, 1992.
93.
Levkowitz G, Klapper LN et al. Coupling of the c-Cbl protooncogene product to ErbB1/EGF-receptor but not to other ErbB proteins. Oncogene 12 (5): 1117-1125, 1996.
94.
Lewis GD, Figari I et al. Differential responses of human tumor cell lines to antip185HER2 monoclonal antibodies. Cancer Immunol Immunother 37 (4): 255-263, 1993.
95.
Lewis S, Locker A et al. Expression of epidermal growth factor receptor in breast
carcinoma. J Clin Pathol 43 (5): 385-389, 1990.
96.
Leygue E, Dotzlaw H et al. Altered estrogen receptor α and β messenger RNA expression
during human breast tumorigenesis. Cancer Res 58 (15): 3197-3201, 1998.
97.
Leygue E, Hall RE et al. Oestrogen receptor-α variant mRNA expression in primary human
breast tumours and matched lymph node metastases. Br J Cancer 79 (5-6): 978-983, 1999.
98.
Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new
therapeutic combination strategies. Biomed Pharmacother 57 (10): 447-451, 2003.
99.
Livingston RB, Esteva FJ. Chemotherapy and herceptin for HER2(+) metastatic breast
cancer: the best drug? Oncologist 6 (4): 315-316, 2001.
100. Lodge AJ, Anderson JJ et al. Type 1 growth factor receptor expression in node positive
breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 56 (4): 300-304,
2003.
101. Longy M, Duboue B et al. Method for the purification of tissue DNA suitable for PCR after
fixation with Bouin's fluid. Uses and limitations in microsatellite typing. Diagn Mol Pathol
6 (3): 167-173, 1997.
102. Macias A, Azavedo E et al. Receptors for epidermal growth factor in human mammary
carcinomas and their metastases. Anticancer Res 6 (4): 849-851, 1986.
103. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers
and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30 (3): 259265, 2000.
104. Mass R, Sanders C, Kasian C. The concordance between the clinical trials assay (CTA) and
fluorescence in situ hybridization (FISH) in Herceptin(R) pivotal trials. Proc Am Soc Clin
Oncol 19 (75a): 2000.
105. McKenzie SJ, Marks PJ et al. Generation and characterization of monoclonal antibodies
specific for the human neu oncogene product, p185. Oncogene 4 (5): 543-548, 1989.
72
106. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene
19 (56): 6550-6565, 2000.
107. Molina MA, Codony-Servat J et al. Trastuzumab (herceptin), a humanized anti-Her2
receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in
breast cancer cells. Cancer Res 61 (12): 4744-4749, 2001.
108. Moreno A, Lloveras B et al. Ductal carcinoma in situ of the breast: correlation between
histologic classifications and biologic markers. Mod Pathol 10 (11): 1088-1092, 1997.
109. Naidu R, Yadav M et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J
Cancer 78 (10): 1385-1390, 1998.
110. Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer
Res Treat 44 (1): 1-22, 1997.
111. Newby JC, Johnston SR et al. Expression of epidermal growth factor receptor and c-erbB2
during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3
(9): 1643-1651, 1997.
112. Nicholson RI, Hutcheson IR et al. Modulation of epidermal growth factor receptor in
endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8 (3):
175-182, 2001.
113. Niehans GA, Singleton TP et al. Stability of HER-2/neu expression over time and at
multiple metastatic sites. J Natl Cancer Inst 85 (15): 1230-1235, 1993.
114. Padhy LC, Shih C et al. Identification of a phosphoprotein specifically induced by the
transforming DNA of rat neuroblastomas. Cell 28 (4): 865-871, 1982.
115. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer
Metastasis Rev 8 (2): 98-101, 1989.
116. Pallis L, Wilking N et al. Receptors for estrogen and progesterone in breast carcinoma in
situ. Anticancer Res 12 (6B): 2113-2115, 1992.
117. Pardue ML, Gall JG. Molecular hybridization of radioactive DNA to the DNA of
cytological preparations. Proc Natl Acad Sci U S A 64 (2): 600-604, 1969.
118. Pauletti G, Dandekar S et al. Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ
hybridization and immunohistochemistry. J Clin Oncol 18 (21): 3651-3664, 2000.
119. Pauletti G, Godolphin W et al. Detection and quantitation of HER-2/neu gene amplification
in human breast cancer archival material using fluorescence in situ hybridization.
Oncogene 13 (1): 63-72, 1996.
120. Pawlowski V, Revillion F et al. Prognostic value of the type I growth factor receptors in a
large series of human primary breast cancers quantified with a real-time reverse
transcription-polymerase chain reaction assay. Clin Cancer Res 6 (11): 4217-4225, 2000.
73
121. Pedersen MW, Meltorn M et al. The type III epidermal growth factor receptor mutation.
Biological significance and potential target for anti-cancer therapy. Ann Oncol 12 (6): 745760, 2001.
122. Penault-Llorca F, Adelaide J et al. Optimization of immunohistochemical detection of
ERBB2 in human breast cancer: impact of fixation. J Pathol 173 (1): 65-75, 1994.
123. Plowman GD, Culouscou JM et al. Ligand-specific activation of HER4/p180erbB4, a
fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A
90 (5): 1746-1750, 1993.
124. Plowman GD, Whitney GS et al. Molecular cloning and expression of an additional
epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A 87 (13): 49054909, 1990.
125. Polosa R, Prosperini G et al. Expression of c-erbB receptors and ligands in human
bronchial mucosa. Am J Respir Cell Mol Biol 20 (5): 914-923, 1999.
126. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in
normal human adult and fetal tissues. Oncogene 5 (7): 953-962, 1990.
127. Press MF, Hung G et al. Sensitivity of HER-2/neu antibodies in archival tissue samples:
potential source of error in immunohistochemical studies of oncogene expression. Cancer
Res 54 (10): 2771-2777, 1994.
128. Quinn CM, Ostrowski JL et al. c-erbB-3 protein expression in human breast cancer:
comparison with other tumour variables and survival. Histopathology 25 (3): 247-252,
1994.
129. Rajkumar T, Gooden CS et al. Expression of the c-erbB-3 protein in gastrointestinal tract
tumours determined by monoclonal antibody RTJ1. J Pathol 170 (3): 271-278, 1993.
130. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive
marker in breast cancer: a paradigm for the development of other macromolecular markers
– a review. Gene 159 (1): 19-27, 1995.
131. Ravdin PM, Green S et al. Prognostic significance of progesterone receptor levels in
estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen:
results of a prospective Southwest Oncology Group study. J Clin Oncol 10 (8): 1284-1291,
1992.
132. Rennstam K, Baldetorp B et al. Chromosomal rearrangements and oncogene amplification
precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 61 (3):
1214-1219, 2001.
133. Ricketts D, Turnbull L et al. Estrogen and progesterone receptors in the normal female
breast. Cancer Res 51 (7): 1817-1822, 1991.
134. Rios MA, Macias A et al. Receptors for epidermal growth factor and estrogen as predictors
of relapse in patients with mammary carcinoma. Anticancer Res 8 (1): 173-176, 1988.
74
135. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73 (1):
5-12, 1996.
136. Roger P, Sahla ME et al. Decreased expression of estrogen receptor β protein in
proliferative preinvasive mammary tumors. Cancer Res 61 (6): 2537-2541, 2001.
137. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor,
Predictive Factor, and Target for Therapy. Oncologist 3 (4): 237-252, 1998.
138. Rossouw JE, Anderson GL et al. Risks and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results From the Women's Health Initiative randomized
controlled trial. JAMA 288 (3): 321-333, 2002.
139. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 12 Suppl 1: S3-S8, 2001.
140. Sainsbury JR, Malcolm AJ et al. Presence of epidermal growth factor receptor as an
indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38 (11): 1225-1228,
1985.
141. Salomon DS, Brandt R et al. Epidermal growth factor-related peptides and their receptors
in human malignancies. Crit Rev Oncol Hematol 19 (3): 183-232, 1995.
142. Sartor CI, Zhou H et al. Her4 mediates ligand-dependent antiproliferative and
differentiation responses in human breast cancer cells. Mol Cell Biol 21 (13): 4265-4275,
2001.
143. Sawyer C, Hiles I et al. Two erbB-4 transcripts are expressed in normal breast and in most
breast cancers. Oncogene 17 (7): 919-924, 1998.
144. Seidman AD, Fornier MN et al. Weekly trastuzumab and paclitaxel therapy for metastatic
breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
J Clin Oncol 19 (10): 2587-2595, 2001.
145. Shimizu C, Fukutomi T et al. c-erbB-2 protein overexpression and p53 immunoreaction in
primary and recurrent breast cancer tissues. J Surg Oncol 73 (1): 17-20, 2000.
146. Shoker BS, Jarvis C et al. Estrogen receptor-positive proliferating cells in the normal and
precancerous breast. Am J Pathol 155 (6): 1811-1815, 1999.
147. Slamon D. Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 4
(Sa): 24-29, 2000.
148. Slamon DJ, Clark GM et al. Human breast cancer: correlation of relapse and survival with
amplification of the HER-2/neu oncogene. Science 235 (4785): 177-182, 1987.
149. Slamon DJ, Godolphin W et al. Studies of the HER-2/neu proto-oncogene in human breast
and ovarian cancer. Science 244 (4905): 707-712, 1989.
150. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody
against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344
(11): 783-792, 2001.
75
151. Sliwkowski MX, Lofgren JA et al. Nonclinical studies addressing the mechanism of action
of trastuzumab (Herceptin). Semin Oncol 26 (4 Suppl 12): 60-70, 1999.
152. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling
pathways. Biol Reprod 58 (3): 627-632, 1998.
153. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor β in breast cancer. Br J
Surg 87 (4): 405-409, 2000.
154. Spyratos F, Ferrero-Pous M et al. Correlation between MIB-1 and other proliferation
markers: clinical implications of the MIB-1 cutoff value. Cancer 94 (8): 2151-2159, 2002.
155. Srinivasan R, Benton E et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4
growth factor receptors and their ligands, neuregulin-1 α, neuregulin-1 β, and betacellulin,
in normal endometrium and endometrial cancer. Clin Cancer Res 5 (10): 2877-2883, 1999.
156. Srinivasan R, Gillett CE et al. Nuclear expression of the c-erbB-4/HER-4 growth factor
receptor in invasive breast cancers. Cancer Res 60 (6): 1483-1487, 2000.
157. Srinivasan R, Poulsom R et al. Expression of the c-erbB-4/HER4 protein and mRNA in
normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol
185 (3): 236-245, 1998.
158. Stabenow R, Eisinger B. Brustkrebs. Epidemiologische Daten zum weiblichen Brustkrebs
aus dem Gemeinsamen Krebsregister der Länder Berlin, Brandenburg, MecklenburgVorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Schriftenreihe
des GKR 1: 2001.
159. Stal O, Sullivan S et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and
radiotherapy of breast cancer. Eur J Cancer 31A (13-14): 2185-2190, 1995.
160. Stancovski I, Hurwitz E et al. Mechanistic aspects of the opposing effects of monoclonal
antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 88 (19):
8691-8695, 1991.
161. Stoica A, Saceda M et al. Regulation of estrogen receptor-α gene expression by epidermal
growth factor. J Endocrinol 165 (2): 371-378, 2000.
162. Suo Z, Berner HS et al. Estrogen receptor-α and C-ERBB-4 expression in breast
carcinomas. Virchows Arch 439 (1): 62-69, 2001.
163. Suo Z, Emilsen E et al. Type 1 protein tyrosine kinases in benign and malignant breast
lesions. Histopathology 33 (6): 514-521, 1998.
164. Suo Z, Risberg B et al. EGFR family expression in breast carcinomas. c-erbB-2 and cerbB-4 receptors have different effects on survival. J Pathol 196 (1): 17-25, 2002.
165. Tang CK, Concepcion XZ et al. Ribozyme-mediated down-regulation of ErbB-4 in
estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Cancer Res 59 (20): 5315-5322, 1999.
76
166. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in
primary and metastatic breast cancer. Cancer Res 61 (14): 5345-5348, 2001.
167. Taylor JM, Mitchell WM, Cohen S. Characterization of the binding protein for epidermal
growth factor. J Biol Chem 249 (7): 2188-2194, 1974.
168. Taylor JM, Mitchell WM, Cohen S. Characterization of the high molecular weight form of
epidermal growth factor. J Biol Chem 249 (10): 3198-3203, 1974.
169. Tovey SM, Witton CJ et al. Outcome and human epidermal growth factor receptor (HER)
1-4 status in invasive breast carcinomas with proliferation indices evaluated by
bromodeoxyuridine labelling. Breast Cancer Res 6 (3): R246-R251, 2004.
170. Travis A, Pinder SE et al. C-erbB-3 in human breast carcinoma: expression and relation to
prognosis and established prognostic indicators. Br J Cancer 74 (2): 229-233, 1996.
171. Tsuda H, Hirohashi S et al. Correlation between long-term survival in breast cancer
patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and
c-erbB-2/ear-1. Cancer Res 49 (11): 3104-3108, 1989.
172. Tsuda H, Iwaya K et al. p53 mutations and c-erbB-2 amplification in intraductal and
invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84 (4): 394-401,
1993.
173. Tsutsui S, Kataoka A et al. Prognostic and predictive value of epidermal growth factor
receptor in recurrent breast cancer. Clin Cancer Res 8 (11): 3454-3460, 2002.
174. Tzahar E, Waterman H et al. A hierarchical network of interreceptor interactions
determines signal transduction by Neu differentiation factor/neuregulin and epidermal
growth factor. Mol Cell Biol 16 (10): 5276-5287, 1996.
175. Ullrich A, Coussens L et al. Human epidermal growth factor receptor cDNA sequence and
aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309
(5967): 418-425, 1984.
176. Vladusic EA, Hornby AE et al. Expression of estrogen receptor β messenger RNA variant
in breast cancer. Cancer Res 58 (2): 210-214, 1998.
177. Vogel CL, Cobleigh MA et al. First-line Herceptin monotherapy in metastatic breast
cancer. Oncology 61 Suppl 2: 37-42, 2001.
178. Vogel CL, Cobleigh MA et al. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (3): 719726, 2002.
179. Vogt U, Bielawski K et al. Amplification of erbB-4 oncogene occurs less frequently than
that of erbB-2 in primary human breast cancer. Gene 223 (1-2): 375-380, 1998.
180. von Minckwitz G, Brunnert K et al. Evidenz-basierte Empfehlungen zur Behandlung von
lokoregionär und fernmetastasierten Mammakarzinomen. Zentralbl Gynakol 124 (5): 293303, 2002.
77
181. Walker RA, Camplejohn RS. DNA flow cytometry of human breast carcinomas and its
relationship to transferrin and epidermal growth factor receptors. J Pathol 150 (1): 37-42,
1986.
182. Witton CJ, Reeves JR et al. Expression of the HER1-4 family of receptor tyrosine kinases
in breast cancer. J Pathol 200 (3): 290-297, 2003.
183. Wright C, Nicholson S et al. Relationship between c-erbB-2 protein product expression and
response to endocrine therapy in advanced breast cancer. Br J Cancer 65 (1): 118-121,
1992.
184. Yakes FM, Chinratanalab W et al. Herceptin-induced inhibition of phosphatidylinositol-3
kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor
action. Cancer Res 62 (14): 4132-4141, 2002.
185. Yang XD, Jia XC et al. Development of ABX-EGF, a fully human anti-EGF receptor
monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 (1): 17-23, 2001.
186. Yang XD, Jia XC et al. Eradication of established tumors by a fully human monoclonal
antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Cancer Res 59 (6): 1236-1243, 1999.
187. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl 2: 113, 2001.
188. Yokota J, Yamamoto T et al. Amplification of c-erbB-2 oncogene in human
adenocarcinomas in vivo. Lancet 1 (8484): 765-767, 1986.
189. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 22 (7): 673680, 2000.
190. Zhou W, Carpenter G. ErbB-4: a receptor tyrosine kinase. Inflamm Res 51 (2): 91-101,
2002.
`